Upcoming event

Interview with Dr. Caffo

Dr. Caffo talked about the CHEIRON study, a multicentric phase II randomized trial of docetaxel (D) plus enzalutamide (E) versus docetaxel (D) as first-line chemotherapy for patients (pts) with metastatic castration-resistant prostate cancer (mCRPC).